You are here

  • Home
  • Archive
  • Volume 30, Issue 8
  • Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Article Text

Article menu

See original article:

Download PDFPDF

Miscellaneous
Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Free

https://doi.org/10.1136/ijgc-2019-001012corr2

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Mayadev J, Zamarin D, Deng W, et al. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer 2019;30:701–4. doi: 10.1136/ijgc-2019-001012

    For this article, the authors noticed that their updated funding statement was incorrect. The correct funding statement is ‘This study was supported by National Institute of Health grants to NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868).’